67
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients

, , &
Pages 1355-1359 | Published online: 23 Nov 2010

References

  • EpsteinSPAhdootMMarcusEAsbellPAComparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cellsJ Ocul Pharmacol Ther200925211311919284328
  • NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther200118520521511783457
  • de Saint JeanMBrignoleFBringuierAFBauchetAFeldmannGBaudouinCEffects of benzalkonium chloride on growth and survival of Chang conjunctival cellsInvest Ophthalmol Vis Sci199940361963010067965
  • DebbaschCPisellaPJde SaintJMRatPWarnetJMBaudouinCMitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cellsInvest Ophthalmol Vis Sci200142112525253311581193
  • SosneGAlbeirutiARHollisBSiddiqiAEllenbergDKurpakus- WheaterMThymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitroExp Eye Res200683350250716630613
  • YeeRWNorcomEGZhaoXCComparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther200623451151917050493
  • BaudouinCRianchoLWarnetJMBrignoleFIn vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci20074894123412817724196
  • KahookMYNoeckerRJComparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea200827333934318362664
  • KahookMYNoeckerRQuantitative analysis of conjunctival goblet cells after chronic application of topical dropsAdv Ther200825874375118670744
  • HorsleyMBKahookMYEffects of prostaglandin analog therapyon the ocular surface of glaucoma patientsClin Ophthalmol2009329129519668581
  • NagaiNMuraoTOkamotoNItoYComparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epitheliumJ Oleo Sci201059313514120124755
  • SchiffmanRMChristiansonMDJacobsenGReliability and validity of the Ocular Surface Disease IndexArch Ophthalmol2000118561562110815152
  • WaltJGRoweMMSternKLEvaluating the functional impact of dry eye: The Ocular Surface Disease IndexDrug Inf J1997311436
  • RossiGCTinelliCPasinettiGMDry eye syndrome-related quality of life in glaucoma patientsEur J Ophthalmol200919457257919551671
  • EpsteinSPChenDAsbellPAEvaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cellsJ Ocul Pharmacol Ther200925541542419857103
  • FechtnerRDGodfreyDGBudenzDPrevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medicationsCornea201029661862120386433
  • GipsonIKDistribution of mucins at the ocular surfaceExp Eye Res200478337938815106916
  • NetlandPALandryTSullivanEKTravoprost Study GroupTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertensionAm J Ophthalmol2001132447248411589866
  • ParrishRKPalmbergPSheuWPXLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
  • StewartWCKolkerAEStewartJALeechJJacksonALConjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprostAm J Ophthalmol2003135331432012614748